Abstract
Background: Adverse events (AEs) are unintended, harmful effects that occur in clinical trials, particularly in early-phase oncology clinical trials (EPOCT), where the risk of adverse effects from experimental therapies is high. Effective AE identification and management are essential for ensuring patient safety, improving outcomes, and advancing research. Advanced practice providers (APPs) play a key role in detecting and managing AEs, serving as a bridge between clinical care and research. However, their full impact on EPOCT remains underexplored. Purpose: This integrative review examines existing literature on AE identification, reporting, and management in EPOCT. It explores the role of APPs in managing AEs, emphasizing their impact on patient outcomes, clinical trial efficiency, and oncology science. Methods: A systematic search of peer-reviewed literature from 2020 to 2025 was conducted using various databases. Inclusion criteria were studies addressing AE management in EPOCT, patient-reported outcomes (PROs), and APP roles. Studies unrelated to oncology, AE management, or health-care providers were excluded. Results: Findings highlight the variability in AE reporting and the growing utility of electronic PRO tools in capturing timely and accurate data. Advanced practice providers contribute significantly to outpatient AE management, reducing emergency visits and improving treatment adherence. However, challenges remain, including underreporting with clinician-based tools, lack of standardized APP training, and limited comparison to physician-led AE management. Conclusion: APPs serve as key players in enhancing AE reporting and improving clinical trial processes. Future research should focus on standardizing structured training programs for APPs and comparative studies assessing the effectiveness of APP-led care.
References
Barber, F. D., Campbell, E., Yamamura, Y., Patterson, C. J., Hartnett, A. C., Kinahan, H., Miller, V. A., Brink, A. L., Poullard, A., Urschel, G. E., Brantley, A., Cepeda, I. G., Goswami, P., Charles, S., Philip, S., Bresser, S., Musekiwa-Adjei, S., Perez, N., Le, H.,…Dumbrava, E. E. (2022). Management of adverse events in early clinical trials by advanced practice providers in the outpatient setting: The University of Texas MD Anderson Cancer Center experience. Journal of the Advanced Practitioner in Oncology, 13(7), 664–672. https://doi.org/10.6004/jadpro.2022.13.7.2
Biniakewitz, M. D., Kasler, M. K., & Fessele, K. L. (2021). Immune-related adverse events in the older adult with cancer receiving immune checkpoint inhibitor therapy. Asia-Pacific Journal of Oncology Nursing, 8(1), 18–24. https://doi.org/10.4103/apjon.apjon_48_20
Braun-Inglis, C., Boehmer, L. M., Zitella, L. J., Hoffner, B., Shvetsov, Y. B., Berenberg, J. L., Oyer, R. A., & Benson, A. B. (2022). Role of Oncology Advanced practitioners to enhance clinical research. Journal of the Advanced Practitioner in Oncology, 13(2), 107–119. https://doi.org/10.6004/jadpro.2022.13.2.2
da Silva Lopes, A. M., Colomer-Lahiguera, S., Darnac, C., Giacomini, S., Bugeia, S., Gutknecht, G., Spurrier-Bernard, G., Aedo-Lopez, V., Mederos, N., Latifyan, S., Addedo, A., Michielin, O., & Eicher, M. (2023). Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors. Supportive Care in Cancer, 31(8). https://doi.org/10.1007/s00520-023-07934-w
Kennedy, F., Shearsmith, L., Ayres, M., Lindner, O. C., Marston, L., Pass, A., Danson, S., & Velikova, G. (2021). Online monitoring of patient self-reported adverse events in early phase clinical trials: Views from patients, clinicians, and trial staff. Clinical Trials, 18(2), 168–179. https://doi.org/10.1177/1740774520972125
Le-Rademacher, J. G., Hillman, S., Storrick, E., Mahoney, M. R., Thall, P. F., Jatoi, A., & Mandrekar, S. J. (2020). Adverse Event Burden Score—A versatile summary measure for cancer clinical trials. Cancers, 12(11), 3251. https://doi.org/10.3390/cancers12113251
Liukka, M., Steven, A., Moreno, M. F. V., Sara-Aho, A. M., Khakurel, J., Pearson, P., Turunen, H., & Tella, S. (2020). Action after Adverse Events in Healthcare: An Integrative Literature Review. International Journal of Environmental Research and Public Health, 17(13), 4717. https://doi.org/10.3390/ijerph17134717
Lopes, G. S., Tournigand, C., Olswold, C. L., Cohen, R., Kempf, E., Saltz, L., Goldberg, R. M., Hurwitz, H., Fuchs, C., De Gramont, A., & Shi, Q. (2020). Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. Clinical Trials, 18(1), 51–60. https://doi.org/10.1177/1740774520959313
Mathew, A., Doorenbos, A. Z., & Vincent, C. (2020). Symptom Management Theory: Analysis, Evaluation, and Implications for Caring for Adults With Cancer. ANS. Advances in nursing science, 44(3), E93–E112. https://doi.org/10.1097/ANS.0000000000000347
Mazzarella, L., Giugliano, F., Nicolo, E., Esposito, A., Crimini, E., Tini, G., Uliano, J., Corti, C., D’Amico, P., Aliaga, P. T., Valenza, C., Repetto, M., Antonarelli, G., Ascione, L., Vivanet, G., Giachetti, P. B., Minchella, I., Belli, C., Locatelli, M.,…Curigliano, G. (2024). Immune-Related Adverse Event Likelihood score identifies “Pure” IRAEs strongly associated with outcome in a phase I-II trial population. The Oncologist, 29(2), e266–e274. https://doi.org/10.1093/oncolo/oyad239
McMullan, C., Retzer, A., Hughes, S. E., Aiyegbusi, O. L., Bathurst, C., Boyd, A., Coleman, J., Davies, E. H., Denniston, A. K., Dunster, H., Frost, C., Harding, R., Hunn, A., Kyte, D., Malpass, R., McNamara, G., Mitchell, S., Mittal, S., Newsome, P. N.,…Calvert, M. (2023). Development and usability testing of an electronic patient-reported outcome (ePRO) solution for patients with inflammatory diseases in an Advanced Therapy Medicinal Product (ATMP) basket trial. Journal of Patient-Reported Outcomes, 7(1). https://doi.org/10.1186/s41687-023-00634-3
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
Peipert, J. D., Zhao, F., Lee, J., Shen, S., Ip, E., O’Connell, N., Carlos, R. C., Graham, N., Smith, M. L., Gareen, I. F., Raper, P. J., Weiss, M., Kumar, S. K., Rajkumar, S. V., Cella, D., Gray, R., & Wagner, L. I. (2024). Patient-reported adverse events and early treatment discontinuation among patients with multiple myeloma. JAMA Network Open, 7(3), e243854. https://doi.org/10.1001/jamanetworkopen.2024.3854
Veitch, Z. W., Shepshelovich, D., Gallagher, C., Wang, L., Razak, A. R. A., Spreafico, A., Bedard, P. L., Siu, L. L., Minasian, L., & Hansen, A. R. (2021). Underreporting of symptomatic adverse events in phase I clinical trials. JNCI Journal of the National Cancer Institute, 113(8), 980–988. https://doi.org/10.1093/jnci/djab015
Watson, G. A., Veitch, Z. W., Shepshelovich, D., Liu, Z. A., Spreafico, A., Razak, A. R. A., Bedard, P. L., Siu, L. L., Minasian, L., & Hansen, A. R. (2022). Evaluation of the patient experience of symptomatic adverse events on phase I clinical trials using PRO-CTCAE. British Journal of Cancer, 127(9), 1629–1635. https://doi.org/10.1038/s41416-022-01926-z
Xie, T., Zhang, Z., Qi, C., Lu, M., Zhang, X., Li, J., Shen, L., & Peng, Z. (2021). The inconsistent and inadequate reporting of immune-related adverse events in PD-1/PD-L1 inhibitors: A systematic review of randomized controlled clinical trials. The Oncologist, 26(12), e2239–e2246. https://doi.org/10.1002/onco.13940
